<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00399542</url>
  </required_header>
  <id_info>
    <org_study_id>0211SIB-0432</org_study_id>
    <nct_id>NCT00399542</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation</brief_title>
  <official_title>Phase 3, 12-Week, Multicenter, Double-Blind, Randomized, Efficacy and Safety Study of Lubiprostone for the Treatment of Irritable Bowel Syndrome With Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sucampo Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sucampo Pharma Americas, LLC</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the efficacy and safety of administration of
      lubiprostone in patients with irritable bowel syndrome with constipation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Responder Status</measure>
    <time_frame>12 weeks</time_frame>
    <description>Overall responder: monthly responder for at least 2 out of 3 months
Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Month 1 Spontaneous Bowel Movement Rates Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>Any bowel movement not associated with rescue medication use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Stool Consistency Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Bowel Straining Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Constipation Severity Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Symptom Relief</measure>
    <time_frame>28 days</time_frame>
    <description>3 = Significantly worse, -2 = Moderately worse,
1 = A little bit worse, 0 = Unchanged, 1 = A little bit relieved, 2 = Moderately relieved, 3 = Significantly relieved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Responder Rate</measure>
    <time_frame>28 days</time_frame>
    <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Responder Rate</measure>
    <time_frame>28 days</time_frame>
    <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Responder Rate</measure>
    <time_frame>28 days</time_frame>
    <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Abdominal Pain Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Abdominal Pain Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Abdominal Pain Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Abdominal Bloating Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Abdominal Bloating Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Abdominal Bloating Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Spontaneous Bowel Movement Rates Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>Any bowel movement not associated with rescue medication use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Spontaneous Bowel Movement Rates Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>Any bowel movement not associated with rescue medication use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Stool Consistency Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Stool Consistency Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Bowel Straining Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Bowel Straining Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Constipation Severity Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Constipation Severity Change From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Symptom Relief</measure>
    <time_frame>28 days</time_frame>
    <description>3 = Significantly worse, -2 = Moderately worse,
1 = A little bit worse, 0 = Unchanged, 1 = A little bit relieved, 2 = Moderately relieved, 3 = Significantly relieved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Symptom Relief</measure>
    <time_frame>28 days</time_frame>
    <description>3 = Significantly worse, -2 = Moderately worse,
1 = A little bit worse, 0 = Unchanged, 1 = A little bit relieved, 2 = Moderately relieved, 3 = Significantly relieved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Quality of Life Change From Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>IBS-QOL questionnaire included 34 questions with 5 possible responses yielding the following sub-categories: dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual, and relationship Results range from 34 (low) to 100 (high); meaningful clinical improvement=14 point increase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Bowel Movement Rates Change From Baseline</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Bowel Movement Rates Change From Baseline</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Bowel Movement Rates Change From Baseline</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">581</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Constipation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older

          -  Stable fiber therapy

          -  Normal colonoscopy/sigmoidoscopy

          -  Able to refrain from use of medications known to treat or associated with constipation
             symptoms

          -  Experiences abdominal discomfort/pain associated with bowel movements

          -  Reports decreased bowel movement frequency and/or other symptoms associated with
             constipation

        Exclusion Criteria:

          -  Diarrhea-predominant or alternating (diarrhea &amp; constipation cycling) IBS, or
             constipation other than that associated with IBS

          -  Open gastrointestinal or abdominal surgery prior to IBS onset

          -  Organic bowel disorder, mechanical bowel obstruction, pseudo-obstruction, unexplained
             weight loss or rectal bleeding

          -  Uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric
             disorder, other systemic disease, or abnormal laboratory tests per investigator
             discretion

          -  If female, is currently pregnant or nursing, or plans to become pregnant or nurse
             during the clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sucampo Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2006</study_first_submitted>
  <study_first_submitted_qc>November 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2006</study_first_posted>
  <results_first_submitted>October 7, 2008</results_first_submitted>
  <results_first_submitted_qc>October 29, 2008</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2008</results_first_posted>
  <last_update_submitted>September 25, 2013</last_update_submitted>
  <last_update_submitted_qc>September 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome With Constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled 05/19/05; last subject observed 08/02/06, at 65 centers across the US</recruitment_details>
      <pre_assignment_details>Subjects were enrolled after an up to 4 week screening period to meet inclusion/exclusion criteria and randomized on Day 0</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lubiprostone</title>
          <description>Subjects who received active drug</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects who received placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lubiprostone</title>
          <description>Subjects who received active drug</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects who received placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="379"/>
            <count group_id="B2" value="192"/>
            <count group_id="B3" value="571"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="12.93"/>
                    <measurement group_id="B2" value="47.3" spread="13.34"/>
                    <measurement group_id="B3" value="46.1" spread="13.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="343"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="3.15"/>
                    <measurement group_id="B2" value="65.0" spread="3.34"/>
                    <measurement group_id="B3" value="64.8" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Responder Status</title>
        <description>Overall responder: monthly responder for at least 2 out of 3 months
Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
        <time_frame>12 weeks</time_frame>
        <population>Intention to treat (ITT), without Last Observational Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Responder Status</title>
          <description>Overall responder: monthly responder for at least 2 out of 3 months
Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
          <population>Intention to treat (ITT), without Last Observational Carried Forward (LOCF).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>70.6% improvement in response with lubiprostone at 90% statistical power</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>No adjustment</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by pooled center, used to test the null hypothesis of equal rates between the 2 groups vs. the alternate hypothesis of non-equality</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Spontaneous Bowel Movement Rates Change From Baseline</title>
        <description>Any bowel movement not associated with rescue medication use</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Spontaneous Bowel Movement Rates Change From Baseline</title>
          <description>Any bowel movement not associated with rescue medication use</description>
          <population>ITT with LOCF</population>
          <units>spontaneous bowel movements (SBMs)/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="3.071"/>
                    <measurement group_id="O2" value="1.29" spread="2.934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.391</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Stool Consistency Change From Baseline</title>
        <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Stool Consistency Change From Baseline</title>
          <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.673"/>
                    <measurement group_id="O2" value="-0.37" spread="0.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Bowel Straining Change From Baseline</title>
        <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Bowel Straining Change From Baseline</title>
          <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.719"/>
                    <measurement group_id="O2" value="-0.42" spread="0.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.163</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Constipation Severity Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Constipation Severity Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.606"/>
                    <measurement group_id="O2" value="-0.33" spread="0.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.185</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Symptom Relief</title>
        <description>3 = Significantly worse, -2 = Moderately worse,
1 = A little bit worse, 0 = Unchanged, 1 = A little bit relieved, 2 = Moderately relieved, 3 = Significantly relieved</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Symptom Relief</title>
          <description>3 = Significantly worse, -2 = Moderately worse,
1 = A little bit worse, 0 = Unchanged, 1 = A little bit relieved, 2 = Moderately relieved, 3 = Significantly relieved</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="1.058"/>
                    <measurement group_id="O2" value="0.60" spread="1.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.300</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Responder Rate</title>
        <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
        <time_frame>28 days</time_frame>
        <population>ITT without LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Responder Rate</title>
          <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
          <population>ITT without LOCF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.303</p_value>
            <p_value_desc>Sequential closed testing procedures were employed</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by pooled center, used to test the null hypothesis of equal rates between the 2 groups vs. the alternate hypothesis of non-equality</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Responder Rate</title>
        <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
        <time_frame>28 days</time_frame>
        <population>ITT without LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Responder Rate</title>
          <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
          <population>ITT without LOCF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>Sequential closed testing procedures were employed</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by pooled center, used to test the null hypothesis of equal rates between the 2 groups vs. the alternate hypothesis of non-equality</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Responder Rate</title>
        <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
        <time_frame>28 days</time_frame>
        <population>ITT without LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Responder Rate</title>
          <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase; AND patient did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
          <population>ITT without LOCF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>Sequential closed testing procedures were employed</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by pooled center, used to test the null hypothesis of equal rates between the 2 groups vs. the alternate hypothesis of non-equality</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Abdominal Pain Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Abdominal Pain Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.600"/>
                    <measurement group_id="O2" value="-0.29" spread="0.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.663</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Abdominal Pain Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Abdominal Pain Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.707"/>
                    <measurement group_id="O2" value="-0.33" spread="0.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.224</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Abdominal Pain Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Abdominal Pain Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.746"/>
                    <measurement group_id="O2" value="-0.35" spread="0.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Abdominal Bloating Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Abdominal Bloating Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.614"/>
                    <measurement group_id="O2" value="-0.28" spread="0.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.945</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Abdominal Bloating Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Abdominal Bloating Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.741"/>
                    <measurement group_id="O2" value="-0.33" spread="0.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.352</p_value>
            <method>van Elteren nonparametric test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Abdominal Bloating Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Abdominal Bloating Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.760"/>
                    <measurement group_id="O2" value="-0.35" spread="0.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.180</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Spontaneous Bowel Movement Rates Change From Baseline</title>
        <description>Any bowel movement not associated with rescue medication use</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Spontaneous Bowel Movement Rates Change From Baseline</title>
          <description>Any bowel movement not associated with rescue medication use</description>
          <population>ITT with LOCF</population>
          <units>SBMs/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="3.191"/>
                    <measurement group_id="O2" value="1.39" spread="3.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.275</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Spontaneous Bowel Movement Rates Change From Baseline</title>
        <description>Any bowel movement not associated with rescue medication use</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Spontaneous Bowel Movement Rates Change From Baseline</title>
          <description>Any bowel movement not associated with rescue medication use</description>
          <population>ITT with LOCF</population>
          <units>SBMs/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="3.061"/>
                    <measurement group_id="O2" value="1.42" spread="3.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.722</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Stool Consistency Change From Baseline</title>
        <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Stool Consistency Change From Baseline</title>
          <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.700"/>
                    <measurement group_id="O2" value="-0.41" spread="0.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.177</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Stool Consistency Change From Baseline</title>
        <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Stool Consistency Change From Baseline</title>
          <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.686"/>
                    <measurement group_id="O2" value="-0.39" spread="0.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Bowel Straining Change From Baseline</title>
        <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Bowel Straining Change From Baseline</title>
          <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.817"/>
                    <measurement group_id="O2" value="-0.50" spread="0.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.110</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Bowel Straining Change From Baseline</title>
        <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Bowel Straining Change From Baseline</title>
          <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.813"/>
                    <measurement group_id="O2" value="-0.50" spread="0.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.146</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Constipation Severity Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Constipation Severity Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.732"/>
                    <measurement group_id="O2" value="-0.42" spread="0.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.373</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Constipation Severity Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Constipation Severity Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.760"/>
                    <measurement group_id="O2" value="-0.42" spread="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.339</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Symptom Relief</title>
        <description>3 = Significantly worse, -2 = Moderately worse,
1 = A little bit worse, 0 = Unchanged, 1 = A little bit relieved, 2 = Moderately relieved, 3 = Significantly relieved</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Symptom Relief</title>
          <description>3 = Significantly worse, -2 = Moderately worse,
1 = A little bit worse, 0 = Unchanged, 1 = A little bit relieved, 2 = Moderately relieved, 3 = Significantly relieved</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="1.140"/>
                    <measurement group_id="O2" value="0.55" spread="1.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Symptom Relief</title>
        <description>3 = Significantly worse, -2 = Moderately worse,
1 = A little bit worse, 0 = Unchanged, 1 = A little bit relieved, 2 = Moderately relieved, 3 = Significantly relieved</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Symptom Relief</title>
          <description>3 = Significantly worse, -2 = Moderately worse,
1 = A little bit worse, 0 = Unchanged, 1 = A little bit relieved, 2 = Moderately relieved, 3 = Significantly relieved</description>
          <population>ITT with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="1.249"/>
                    <measurement group_id="O2" value="0.56" spread="1.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Quality of Life Change From Baseline</title>
        <description>IBS-QOL questionnaire included 34 questions with 5 possible responses yielding the following sub-categories: dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual, and relationship Results range from 34 (low) to 100 (high); meaningful clinical improvement=14 point increase</description>
        <time_frame>12 weeks</time_frame>
        <population>ITT without LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Quality of Life Change From Baseline</title>
          <description>IBS-QOL questionnaire included 34 questions with 5 possible responses yielding the following sub-categories: dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual, and relationship Results range from 34 (low) to 100 (high); meaningful clinical improvement=14 point increase</description>
          <population>ITT without LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="17.46"/>
                    <measurement group_id="O2" value="13.4" spread="16.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Bowel Movement Rates Change From Baseline</title>
        <time_frame>28 days</time_frame>
        <population>ITT, with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Bowel Movement Rates Change From Baseline</title>
          <population>ITT, with LOCF</population>
          <units>bowel movements (BMs)/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="2.787"/>
                    <measurement group_id="O2" value="0.87" spread="3.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>van Elteren nonparametric test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Bowel Movement Rates Change From Baseline</title>
        <time_frame>28 days</time_frame>
        <population>ITT, with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Bowel Movement Rates Change From Baseline</title>
          <population>ITT, with LOCF</population>
          <units>BMs/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="2.875"/>
                    <measurement group_id="O2" value="0.95" spread="3.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.290</p_value>
            <method>van Elteren nonparametric test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Bowel Movement Rates Change From Baseline</title>
        <time_frame>28 days</time_frame>
        <population>ITT, with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Bowel Movement Rates Change From Baseline</title>
          <population>ITT, with LOCF</population>
          <units>BMs/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="2.757"/>
                    <measurement group_id="O2" value="0.97" spread="3.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.495</p_value>
            <method>van Elteren nonparametric test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lubiprostone</title>
          <description>Subjects who received active drug</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects who received placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestine gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67"/>
                <counts group_id="E2" subjects_affected="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="384"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="384"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="384"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raymond Panas, PhD</name_or_title>
      <organization>Sucampo Pharmaceuticals, Inc.</organization>
      <phone>301-961-3400</phone>
      <email>info@sucampo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

